Oblita Therapeutics

Oblita Therapeutics

Foundation date

08/03/2016

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Anti-infectives

Therapeutic areas

• #Infectious and parasitic diseases

Oblita Therapeutics is a global health research & development start-up company. Our goal is to close current therapeutic gaps and improve the quality of life of those suffering from “forgotten” (neglected) diseases. Oblita Therapeutics’ lead program is focused on the development of a new drug (D121) to treat leishmaniasis (starting phase II). We have convincing preclinical results on the effectiveness of D121 against Cryptosporidium Parvum infection, Chagas Disease, and Fungal Infections.